Artelo Biosciences
NASDAQ: ARTLSolana Beach, US · Nevada corporation
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, with a pipeline of drug candidates aimed at treating cancer and related conditions.
BiotechHealthtech
Founders & leadership
GD
Gregory D. GorgasExecutive
PO
Peter O'BrienSenior Vice President - European Operations
Board
CM
Connie MatsuiBoard director
SK
Steven KellyBoard director
DB
Douglas BlayneyBoard director
GR
Gregory R. ReyesBoard director
TA
Tamara A. FavoritoBoard director
RM
R. Martin EmanueleBoard director
Reported raises · per SEC filings
Form D private placements$33.4M disclosed across 14 of 15 rounds · 2017–2026
▶$11MraisedApr 2026 · 2 investors · BiotechnologyRule 506(b)
▶$11MraisedApr 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- R. Martin EmanueleDirector
- Connie MatsuiDirector
- Mark SpringExecutive Officer
- Gregory R. ReyesDirector
- Tamara A. FavoritoDirector
- Steven KellyDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $11M
- Amount sold
- $11M
- Sales commissions
- $880K
- Proceeds to insiders
- $575.5K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$113KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$113KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Mark SpringExecutive Officer
- Connie MatsuiDirector
- Gregory R. ReyesDirector
- Tamara A. FavoritoDirector
- R. Martin EmanueleDirector
- Steven KellyDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $113K
- Amount sold
- $113K
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$237.3KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$237.3KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Connie MatsuiDirector
- Tamara A. FavoritoDirector
- Gregory R. ReyesDirector
- Steven KellyDirector
- Mark SpringExecutive Officer, Director
- R. Martin EmanueleDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $237.3K
- Amount sold
- $237.3K
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$315KraisedMar 2026 · 1 investors · BiotechnologyRule 506(b)
▶$315KraisedMar 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory D. GorgasExecutive Officer, Director
- Douglas BlayneyDirector
- Gregory R. ReyesDirector
- R. Martin EmanueleDirector
- Mark SpringExecutive Officer
- Steven KellyDirector
- Connie MatsuiDirector
- Tamara A. FavoritoDirector
- Offering amount
- $315K
- Amount sold
- $315K
- First sale
- Mar 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$500KraisedFeb 2026 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedFeb 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Tamara A. FavoritoDirector
- Gregory D. GorgasExecutive Officer, Director
- R. Martin EmanueleDirector
- Mark SpringExecutive Officer
- Connie MatsuiDirector
- Gregory R. ReyesDirector
- Steven KellyDirector
- Offering amount
- $50.5M
- Amount sold
- $500K
- First sale
- Jan 2026
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3.7MraisedNov 2025 · 14 investors · BiotechnologyRule 506(b)
▶$3.7MraisedNov 2025 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas BlayneyDirector
- Mark SpringExecutive Officer
- Gregory R. ReyesDirector
- Gregory D. GorgasExecutive Officer, Director
- R. Martin EmanueleDirector
- Connie MatsuiDirector
- Steven KellyDirector
- Tamara A. FavoritoDirector
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- First sale
- Oct 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$9.5MraisedAug 2025 · 18 investors · BiotechnologyRule 506(b)
▶$9.5MraisedAug 2025 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory R. ReyesDirector
- Connie MatsuiDirector
- Gregory D. GorgasExecutive Officer, Director
- Steven KellyDirector
- Tamara A. FavoritoDirector
- R. Martin EmanueleDirector
- Douglas BlayneyDirector
- Offering amount
- $9.5M
- Amount sold
- $9.5M
- First sale
- Aug 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.4MraisedJul 2025 · 8 investors · BiotechnologyRule 506(b)
▶$1.4MraisedJul 2025 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Connie MatsuiDirector
- Steven KellyDirector
- Douglas BlayneyDirector
- Gregory R. ReyesDirector
- Tamara A. FavoritoDirector
- R. Martin EmanueleDirector
- Gregory D. GorgasExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $1.4M
- First sale
- Jun 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlapSeeking Alpha23 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
TradingView23 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Robinhood20 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Interactive Strength Acquires Ergatta20 shared keywordsFidelity provides brokerage and investing services for individual retail investors, including commission-free online trading of US stocks and ETFs and fractional share purchases starting at $1. It positions itself as a personal finance and investment provider serving customers pursuing long-term financial goals.
Stocktwits19 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
Simply Wall St18 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
Perplexity17 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies competing with Artelo Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Artelo Biosciences do?
- Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, with a pipeline of drug candidates aimed at treating cancer and related conditions.
- How much funding has Artelo Biosciences raised?
- Artelo Biosciences has disclosed $33.4M raised across 14 of its 15 known rounds.
- Where is Artelo Biosciences headquartered?
- Artelo Biosciences is headquartered in Solana Beach, US.